Overview

A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)

Status:
Completed

Trial end date:
2018-03-15

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy of the triplet of ridaforolimus, dalotuzumab and exemestane compared to the combination of ridaforolimus and exemestane in post-menopausal participants with breast cancer. The primary hypothesis of the study is that the triplet of ridaforolimus, dalotuzumab and exemestane will improve progression free survival (PFS) compared to ridaforolimus and exemestane.

Phase:

Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Antibodies, Monoclonal
Exemestane
Sirolimus